Effects and mechanism of intestinal microbiota changes on Moyamoya disease and other cerebrovascular diseases

Effects of intestinal microbiota changes on Moyamoya disease and other cerebrovascular diseases

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062561

Enrollment

Unknown

Registered

2022-08-11

Start date

2022-08-10

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moyamoya disease and other cerebrovascular diseases

Interventions

Case series:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients meet the diagnostic criteria for Moyamoya disease and other cerebrovascular diseases; 2. The continuity of the experimental project;(3) Patients and their family members give informed consent and fill in the informed consent form

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients with end-stage diseases and mental diseases; 3. Cases who are participating in or have participated in other clinical trials within 3 months; 4. Previous history of intestinal pathogen infection; 5. Oral antibiotics or proton pump inhibitors (PPI) in the past 2 weeks, and immunosuppressive patients.

Design outcomes

Primary

Measure	Time frame
intestinal microbes and metabolites;Basic fibroblast growth factor in blood and cerebrospinal fluid;	—

Countries

China

Contacts

Public ContactXuejing Wang

fccwangxj2@zzu.edu.cn+86 15938782456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026